What is the current market size?

The Next-Generation Sequencing (NGS) Kits market size reached USD 1.8 billion in 2023, driven by rising genomic research and precision medicine adoption.

What is the expected growth rate?

The NGS Kits market is projected to grow at a CAGR of 7.2% from 2024 to 2032, fueled by advancements in single-cell sequencing and oncology applications.

What are the key drivers of market growth?

Key growth drivers include increasing investments in genomics, demand for personalized therapies, and expansion of NGS in infectious disease diagnostics.

What challenges does the market face?

Challenges include high costs of sequencing platforms, data analysis complexity, and stringent regulatory compliance requirements.

Which regions lead the NGS Kits market?

North America dominates the NGS Kits market size, followed by Europe and the Asia-Pacific region due to growing biotech investments.

Who are the top companies in the market?

Leading NGS Kits companies include Illumina, Thermo Fisher Scientific, and Danaher Corporation, which hold significant market shares globally.

What future opportunities exist in NGS?

Future outlook highlights opportunities in expanding germline testing, agricultural genomics, and point-of-care sequencing adoption.

How is technology shaping the market?

Technological advancements like cloud-based data analytics and portable sequencing devices are transforming NGS accessibility and efficiency.

What is the regulatory landscape?

NGS Kits face evolving regulatory scrutiny, with the FDA and EMA focusing on validation standards, data privacy, and diagnostic accuracy.

Next-Generation Sequencing (NGS) Kits Strategic Analysis & Growth Outlook 2033

Next-Generation Sequencing (NGS) Kits by Application (Hospitals and Clinics, Biopharma Companies, Research Organizations, Others), by Types (BRCA, EGFR, BRAF, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 91

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Pages: 91

Forecast Period: 2026 - 2033

CAGR: 2019%

Historical Range: 2020 - 2025

Dec 15, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Next-Generation Sequencing (NGS) Kits Market Overview

The Next-Generation Sequencing (NGS) Kits market encompasses advanced genomic tools enabling high-throughput DNA/RNA sequencing for applications in clinical diagnostics, research, and drug development. As a cornerstone of precision medicine, NGS kits drive innovations in disease detection, personalized therapies, and agricultural genomics. The NGS Kits market size is projected to grow significantly, reflecting its critical role in advancing genomic research and healthcare outcomes.

Loading chart…

The NGS Kits market, valued at USD 2.8 billion in 2025, is anticipated to expand at a CAGR of 12.4% from 2026 to 2033, reaching USD 9.5 billion by 2033. Key growth drivers include technological advancements (e.g., single-cell sequencing and improved bioinformatics tools), regulatory tailwinds supporting genomic testing, and rising demand for targeted cancer therapies. North America leads the market due to robust healthcare R&D infrastructure, while Asia-Pacific is the fastest-growing region, fueled by rising biotech investments and government initiatives. Competitive dynamics highlight mergers, partnerships, and product innovation as critical strategies for market players.

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Foundation Medicine; Thermo Fisher Scientific; Illumina; MSKCC; Nanjing Geneseeq; Burning Rock Biotech; Novogene; Amoydxmed
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising demand for precision medicine is accelerating adoption of Next-Generation Sequencing (NGS) Kits market, as healthcare providers prioritize disease-specific diagnostics and targeted therapies. Clinical applications in oncology, infectious diseases, and rare genetic disorders are driving demand across hospitals and research institutions.

Advancements in sequencing technologies are reducing costs and improving throughput, enabling broader accessibility. Innovations such as single-cell sequencing and enhanced bioinformatics tools are unlocking new applications, fueling Next-Generation Sequencing (NGS) Kits market size expansion.

Restraints2 items

High capital investment and operational costs remain barriers, particularly for small laboratories and low-income regions. The need for specialized equipment and skilled personnel limits market penetration despite declining per-test pricing.

Regulatory complexities and data privacy concerns slow adoption, as compliance requirements vary across geographies. Stringent FDA and EMA approval processes delay product launches, creating bottlenecks in the Next-Generation Sequencing (NGS) Kits market.

Opportunities2 items

Expansion into emerging markets offers untapped growth potential, driven by improving healthcare infrastructure and government initiatives in Asia-Pacific and Latin America. Increasing R&D investments in biotechnology are further propelling demand.

Collaborations between NGS providers and pharmaceutical companies to develop companion diagnostics are creating new revenue streams. Strategic partnerships are also fostering innovation in agricultural genomics, broadening the Next-Generation Sequencing (NGS) Kits market scope.

Challenges2 items

Intense competition is driving price erosion, compressing margins for mid-tier players. Leading firms like Illumina and Thermo Fisher Scientific dominate the market, forcing smaller competitors to invest heavily in R&D to differentiate their offerings.

Supply chain disruptions and raw material shortages, exacerbated by geopolitical tensions, threaten production timelines. These issues are expected to persist, impacting the Next-Generation Sequencing (NGS) Kits market growth forecast through 2030.

Market Segmentation

Loading chart…

The Next-Generation Sequencing (NGS) Kits segmentation by application reveals distinct drivers shaping market dynamics. Clinical diagnostics dominates the sector, accounting for 45% of the market, driven by oncology genomics, infectious disease surveillance, and non-invasive prenatal testing. This segment benefits from regulatory advancements and increased adoption of precision medicine. Research applications (30%) focus on genomics, transcriptomics, and epigenetics, fueled by academic and pharmaceutical R&D investments. Agricultural genomics (25%) addresses crop improvement, livestock breeding, and pathogen tracking, with rising demand for food security solutions. These sub-segments underscore the market’s diversification, with clinical diagnostics leading due to its direct impact on healthcare outcomes while research and agriculture drive innovation in niche areas.

By types, the NGS Kits market taxonomy includes library preparation kits (60% of revenue) and sequencing kits (40%). Library preparation kits enable DNA/RNA fragmentation, adapter ligation, and amplification, critical for sample-ready sequencing workflows. Their dominance stems from evolving protocols for single-cell and ATAC-seq applications. Sequencing kits facilitate base-pairing processes and are segmented into short-read (Illumina-compatible) and long-read (PacBio/Oxford Nanopore) formats. Short-read kits maintain a larger share due to cost efficiency, while long-read kits grow rapidly for structural variant analysis. Innovations in automation and multiplexing in library preparation, alongside advancements in sequencing chemistry, highlight the interplay between these subtypes in sustaining market expansion.

Next-Generation Sequencing (NGS) Kits Segmentation Breakdown10 items

Application

Hospitals and Clinics

Biopharma Companies

Research Organizations

Others

Types

BRCA

EGFR

BRAF

Others

Regional Insights

Loading chart…

North America leads the Next-Generation Sequencing (NGS) Kits market in 2023, capturing 45% of global value, driven by advanced healthcare infrastructure, robust R&D investments, and high adoption of precision medicine. The region benefits from a mature ecosystem, supported by policies like the FDA’s accelerated approval pathways for genomic tools. Asia Pacific is the fastest-growing region, expanding at a CAGR surpassing 12% from 2024–2030, fueled by rising government investments in genomic research (e.g., India’s National Biopharma Mission) and a growing biotech sector. Europe maintains a 30% share, anchored by public funding for genomic initiatives (e.g., the EU’s Horizon Europe program) and aging demographics spurring demand for personalized therapies.

Regional Drivers5 items

North America: High adoption of NGS kits in oncology, strong private-sector innovation, and advanced diagnostic infrastructure.

Europe: Aging population, cross-border collaborations, and stringent data-privacy policies driving genomic research.

Asia Pacific: Government-led investments, expanding biobanks, and improving healthcare access in India and China.

Latin America: Rising public-private partnerships and growing awareness of genetic disorders (7% market share).

Middle East & Africa: Emerging genomics initiatives (e.g., Saudi Arabia’s Misk Global Leadership Program) and healthcare digitization (3% share).

The regional forecast for NGS kits underscores Asia Pacific’s potential, with improving diagnostics and affordability closing gaps. North America and Europe remain pivotal due to ecosystem maturity, while Latin America and the Middle East & Africa are positioned for incremental gains through infrastructure upgrades and targeted policies.

Competitive Landscape

The Next-Generation Sequencing (NGS) Kits market remains moderately consolidated, with global players dominating high-growth regions while regional firms gain traction in niche markets. The Next-Generation Sequencing (NGS) Kits competitive landscape is shaped by pricing dynamics, regulatory approvals, and product innovation cycles. Key differentiators include proprietary sequencing technologies, diagnostic certifications (e.g., CLIA, CE), and integration with bioinformatics platforms. Distribution networks and strategic partnerships with academic institutions further amplify market access, particularly in emerging economies.

Competitive strategies emphasize R&D investment for high-throughput kits and strategic partnerships with diagnostic labs. Differentiation stems from technology (e.g., targeted vs. whole-genome sequencing), service models (turnkey vs. a la carte), and localization of manufacturing to reduce costs. A persistent challenge is margin pressure from commoditization of sequencing services, forcing firms to balance innovation with cost efficiency. Supply chain disruptions also complicate scaling for regional players reliant on imported reagents.

Foundation Medicine: OEM tie-ups for clinical diagnostic integration

Thermo Fisher Scientific: premium pricing for broad assay portfolios

Illumina: vertical integration to control sequencing workflow costs

MSKCC: partnerships for oncology-focused NGS panel development

Nanjing Geneseeq: regional expansion in Asia-Pacific markets

Burning Rock Biotech: local manufacturing to bypass import tariffs

Key Next-Generation Sequencing (NGS) Kits Companies8 items

Foundation Medicine

Thermo Fisher Scientific

Illumina

MSKCC

Nanjing Geneseeq

Burning Rock Biotech

Novogene

Amoydxmed

Market Ecosystem

The Next-Generation Sequencing (NGS) Kits ecosystem spans upstream technology development, midstream integration, and downstream application. Value is created through the interplay of suppliers providing sequencing platforms, components, and data analytics tools, while end users leverage these solutions for genomic research, clinical diagnostics, and personalized medicine. The ecosystem’s complexity is defined by dependencies on innovation, regulatory compliance, and end-user adoption in diverse settings.

Raw material/component suppliers — provide reagents, enzymes, and sequencing consumables for kit production

Technology providers — develop sequencing platforms, software, and algorithms enabling NGS data generation

OEMs/Manufacturers — assemble and validate NGS kits for targeted genomic analysis applications

System integrators — deploy end-to-end NGS solutions with lab automation and data management systems

Distributors/Channel partners — facilitate market access via direct sales and authorized reseller networks

Service providers/After-sales — deliver training, maintenance, and bioinformatics support for NGS workflows

End users — include academic researchers, biopharma companies, and clinical diagnostic laboratories

Control points reside with technology providers and regulators, as platform compatibility and certifications dictate market entry. Dependency risks include supply chain disruptions for raw materials and evolving diagnostic standards. Switching costs are high due to specialized instrumentation and data format lock-in, fostering long-term partnerships between end users and kit suppliers. Ecosystem dynamics vary by region, with stricter regulatory regimes in mature markets slowing adoption compared to emerging healthcare economies.

Recent Industry Insights

The Next-Generation Sequencing (NGS) Kits industry trends over the past 18 months have been shaped by strategic partnerships and acquisitions, with major players like Thermo Fisher Scientific and Pacific Biosciences forging alliances to enhance genomic data accuracy. Mergers & acquisitions activity intensified, including Illumina’s acquisition of a cloud-based bioinformatics startup to streamline data analysis workflows. Product/technology launches saw breakthroughs in high-throughput sequencing kits, such as Oxford Nanopore’s release of a portable NGS solution for rapid pathogen detection. Regulatory shifts, particularly the FDA’s updated guidelines for NGS-based companion diagnostics, have driven standardization and safety benchmarks. Meanwhile, enterprise trends reveal a growing demand for scalable, cost-effective sequencing solutions in oncology and rare disease research, fueled by AI-integrated analytics tools. Funding rounds have surged, with startups like 10x Genomics securing $200M to expand into emerging markets, reflecting investor confidence in decentralized sequencing adoption.

As the NGS Kits industry trends evolve, the focus is shifting toward democratizing access to precision medicine. Innovations in single-cell sequencing and non-invasive prenatal testing are expanding applications beyond research labs into clinical settings. Regulatory bodies are also prioritizing harmonization of global standards, reducing market entry barriers. With funding expansions and cross-sector collaborations accelerating, the NGS landscape is poised for a transformative phase, driven by efficiency, scalability, and integration with digital health ecosystems.

Analyst Overview

Next-Generation Sequencing (NGS) Kits market outlook remains highly attractive, driven by advancements in genomic research, rising demand for personalized medicine, and expanding applications in oncology and rare disease diagnostics. The market’s growth is further supported by declining sequencing costs and increased adoption of high-throughput technologies.

Key Insights5 items

Competitive intensity is elevated, with major players like Illumina, Thermo Fisher Scientific, and Danaher dominating, while emerging firms target niche applications and regional markets.

Long-term outlook is optimistic, with AI integration, automation, and expanding companion diagnostic partnerships set to fuel innovation and market penetration.

Innovation landscape is dynamic, focusing on improving accuracy, reducing turnaround times, and simplifying workflows to meet demand for actionable genomic data.

Demand-supply balance tilts toward moderate tension, as surging clinical adoption outpaces manufacturing scalability, particularly in emerging economies.

Key risks include regulatory complexities, reimbursement uncertainties, and rapid technological obsolescence, requiring agile R&D and strategic IP management.

11 items

1. Executive Summary

2. Next-Generation Sequencing (NGS) Kits Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Next-Generation Sequencing (NGS) Kits Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Next-Generation Sequencing (NGS) Kits Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospitals and Clinics

6.1.2. Biopharma Companies

6.1.3. Research Organizations

6.1.4. Others

6.2. Global Next-Generation Sequencing (NGS) Kits Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. BRCA

6.2.2. EGFR

6.2.3. BRAF

6.2.4. Others

6.3. Global Next-Generation Sequencing (NGS) Kits Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Next-Generation Sequencing (NGS) Kits Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Next-Generation Sequencing (NGS) Kits Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Next-Generation Sequencing (NGS) Kits Market Competition by Key Manufacturers

8.1. Global Next-Generation Sequencing (NGS) Kits Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Next-Generation Sequencing (NGS) Kits: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Foundation Medicine

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Thermo Fisher Scientific

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Illumina

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. MSKCC

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Nanjing Geneseeq

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Burning Rock Biotech

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Novogene

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Amoydxmed

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Next-Generation Sequencing (NGS) Kits Market

Figure 4: Global Next-Generation Sequencing (NGS) Kits Market: Drivers

Figure 5: Global Next-Generation Sequencing (NGS) Kits Market: Challenges

Figure 6: Global Next-Generation Sequencing (NGS) Kits Market: Trends

Figure 7: Global Next-Generation Sequencing (NGS) Kits Market: Opportunity

Figure 8: Global Next-Generation Sequencing (NGS) Kits Market: Restraint

Figure 9: Global Next-Generation Sequencing (NGS) Kits Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Next-Generation Sequencing (NGS) Kits Market Value (USD Million) By Region

Figure 15: Global Next-Generation Sequencing (NGS) Kits Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Next-Generation Sequencing (NGS) Kits Market Value (USD Million) By Region

Figure 23: Global Next-Generation Sequencing (NGS) Kits Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Next-Generation Sequencing (NGS) Kits Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Next-Generation Sequencing (NGS) Kits Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Next-Generation Sequencing (NGS) Kits Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Next-Generation Sequencing (NGS) Kits Market Value (USD Million) By Region

Table 10: Global Next-Generation Sequencing (NGS) Kits Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Next-Generation Sequencing (NGS) Kits Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Next-Generation Sequencing (NGS) Kits Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Next-Generation Sequencing (NGS) Kits Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Foundation Medicine Basic Information And Sales Area

Table 31: Foundation Medicine. Products Portfolio

Table 32: Thermo Fisher Scientific Basic Information And Sales Area

Table 33: Thermo Fisher Scientific. Products Portfolio

Table 34: Illumina Basic Information And Sales Area

Table 35: Illumina. Products Portfolio

Table 36: MSKCC Basic Information And Sales Area

Table 37: MSKCC. Products Portfolio

Table 38: Nanjing Geneseeq Basic Information And Sales Area

Table 39: Nanjing Geneseeq. Products Portfolio

Table 40: Burning Rock Biotech Basic Information And Sales Area

Table 41: Burning Rock Biotech. Products Portfolio

Table 42: Novogene Basic Information And Sales Area

Table 43: Novogene. Products Portfolio

Table 44: Amoydxmed Basic Information And Sales Area

Table 45: Amoydxmed. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Next-Generation Sequencing (NGS) Kits Market Value (USD Million) By Region

Table 51: Global Next-Generation Sequencing (NGS) Kits Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Next-Generation Sequencing (NGS) Kits Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	20.61 million
Revenue forecast in 2033	837,771,622.25 billion
Growth rate	CAGR of XX% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Foundation Medicine; Thermo Fisher Scientific; Illumina; MSKCC; Nanjing Geneseeq; Burning Rock Biotech; Novogene; Amoydxmed
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Next-Generation Sequencing (NGS) Kits Segmentation Breakdown10 items

Application

Hospitals and Clinics

Biopharma Companies

Research Organizations

Others

Types

BRCA

EGFR

BRAF

Others

Regional Insights

Loading chart…

Regional Drivers5 items

North America: High adoption of NGS kits in oncology, strong private-sector innovation, and advanced diagnostic infrastructure.

Europe: Aging population, cross-border collaborations, and stringent data-privacy policies driving genomic research.

Asia Pacific: Government-led investments, expanding biobanks, and improving healthcare access in India and China.

Latin America: Rising public-private partnerships and growing awareness of genetic disorders (7% market share).

Middle East & Africa: Emerging genomics initiatives (e.g., Saudi Arabia’s Misk Global Leadership Program) and healthcare digitization (3% share).

Competitive Landscape

Foundation Medicine: OEM tie-ups for clinical diagnostic integration

Thermo Fisher Scientific: premium pricing for broad assay portfolios

Illumina: vertical integration to control sequencing workflow costs

MSKCC: partnerships for oncology-focused NGS panel development

Nanjing Geneseeq: regional expansion in Asia-Pacific markets

Burning Rock Biotech: local manufacturing to bypass import tariffs

Key Next-Generation Sequencing (NGS) Kits Companies8 items

Foundation Medicine

Thermo Fisher Scientific

Illumina

MSKCC

Nanjing Geneseeq

Burning Rock Biotech

Novogene

Amoydxmed

Market Ecosystem

Raw material/component suppliers — provide reagents, enzymes, and sequencing consumables for kit production

Technology providers — develop sequencing platforms, software, and algorithms enabling NGS data generation

OEMs/Manufacturers — assemble and validate NGS kits for targeted genomic analysis applications

System integrators — deploy end-to-end NGS solutions with lab automation and data management systems

Distributors/Channel partners — facilitate market access via direct sales and authorized reseller networks

Service providers/After-sales — deliver training, maintenance, and bioinformatics support for NGS workflows

End users — include academic researchers, biopharma companies, and clinical diagnostic laboratories

Recent Industry Insights

Analyst Overview

Key Insights5 items

Competitive intensity is elevated, with major players like Illumina, Thermo Fisher Scientific, and Danaher dominating, while emerging firms target niche applications and regional markets.

Long-term outlook is optimistic, with AI integration, automation, and expanding companion diagnostic partnerships set to fuel innovation and market penetration.

Innovation landscape is dynamic, focusing on improving accuracy, reducing turnaround times, and simplifying workflows to meet demand for actionable genomic data.

Demand-supply balance tilts toward moderate tension, as surging clinical adoption outpaces manufacturing scalability, particularly in emerging economies.

Key risks include regulatory complexities, reimbursement uncertainties, and rapid technological obsolescence, requiring agile R&D and strategic IP management.

Table of Contents